ES2870920T3 - Inhibidores de CXCR4 y usos de los mismos - Google Patents
Inhibidores de CXCR4 y usos de los mismos Download PDFInfo
- Publication number
- ES2870920T3 ES2870920T3 ES17816163T ES17816163T ES2870920T3 ES 2870920 T3 ES2870920 T3 ES 2870920T3 ES 17816163 T ES17816163 T ES 17816163T ES 17816163 T ES17816163 T ES 17816163T ES 2870920 T3 ES2870920 T3 ES 2870920T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- optionally substituted
- membered
- nitrogen
- sulfur
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CCCC(CC*1)N1C(CC)C1C*CC1 Chemical compound CCCC(CC*1)N1C(CC)C1C*CC1 0.000 description 16
- DHXVGJBLRPWPCS-UHFFFAOYSA-N C1CCOCC1 Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N C1CCNCC1 Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- VICYTAYPKBLQFB-UHFFFAOYSA-N CCOC(C(CBr)=O)=O Chemical compound CCOC(C(CBr)=O)=O VICYTAYPKBLQFB-UHFFFAOYSA-N 0.000 description 2
- UMRZSTCPUPJPOJ-UHFFFAOYSA-N C(C1)C2CC1CC2 Chemical compound C(C1)C2CC1CC2 UMRZSTCPUPJPOJ-UHFFFAOYSA-N 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N C(C1)C2CCN1CC2 Chemical compound C(C1)C2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- ASUQYWCXZRNVRW-UHFFFAOYSA-N C(C1)C2CCNC1C2 Chemical compound C(C1)C2CCNC1C2 ASUQYWCXZRNVRW-UHFFFAOYSA-N 0.000 description 1
- GYLMCBOAXJVARF-UHFFFAOYSA-N C(C1)C2CNC1C2 Chemical compound C(C1)C2CNC1C2 GYLMCBOAXJVARF-UHFFFAOYSA-N 0.000 description 1
- KPUSZZFAYGWAHZ-UHFFFAOYSA-N C(C1)C2CNC1CC2 Chemical compound C(C1)C2CNC1CC2 KPUSZZFAYGWAHZ-UHFFFAOYSA-N 0.000 description 1
- GMOFDANHMUHNBP-UHFFFAOYSA-N C(C1)C2CSC1CC2 Chemical compound C(C1)C2CSC1CC2 GMOFDANHMUHNBP-UHFFFAOYSA-N 0.000 description 1
- SNZSSCZJMVIOCR-UHFFFAOYSA-N C(C1)C2NC1CC2 Chemical compound C(C1)C2NC1CC2 SNZSSCZJMVIOCR-UHFFFAOYSA-N 0.000 description 1
- LKDJYZBKCVSODK-UHFFFAOYSA-N C(C1)C2NC1CNC2 Chemical compound C(C1)C2NC1CNC2 LKDJYZBKCVSODK-UHFFFAOYSA-N 0.000 description 1
- MNILDQSRDHCFJG-UHFFFAOYSA-N C(C1)C2NC1COC2 Chemical compound C(C1)C2NC1COC2 MNILDQSRDHCFJG-UHFFFAOYSA-N 0.000 description 1
- POOPWPIOIMBTOH-UHFFFAOYSA-N C(C1)C2OC1CNC2 Chemical compound C(C1)C2OC1CNC2 POOPWPIOIMBTOH-UHFFFAOYSA-N 0.000 description 1
- NKFZUGIEJYGXMY-UHFFFAOYSA-N C(C1)C2OC1OC2 Chemical compound C(C1)C2OC1OC2 NKFZUGIEJYGXMY-UHFFFAOYSA-N 0.000 description 1
- PGRMVFYQFHCNSA-UHFFFAOYSA-N C(C1)C2OCCN1C2 Chemical compound C(C1)C2OCCN1C2 PGRMVFYQFHCNSA-UHFFFAOYSA-N 0.000 description 1
- ORCQJRXQASSNAQ-UHFFFAOYSA-N C(C1)C2c3ccccc3C1CC2 Chemical compound C(C1)C2c3ccccc3C1CC2 ORCQJRXQASSNAQ-UHFFFAOYSA-N 0.000 description 1
- FTTATHOUSOIFOQ-UHFFFAOYSA-N C(C1)CN2C1CNCC2 Chemical compound C(C1)CN2C1CNCC2 FTTATHOUSOIFOQ-UHFFFAOYSA-N 0.000 description 1
- VLCAUFUDKLGTBG-UHFFFAOYSA-N C(C12)=CC=CC1=C1OC=C2C=C1 Chemical compound C(C12)=CC=CC1=C1OC=C2C=C1 VLCAUFUDKLGTBG-UHFFFAOYSA-N 0.000 description 1
- YVPKKTHVFYAAQN-UHFFFAOYSA-N C1=CN=[I]N=C1 Chemical compound C1=CN=[I]N=C1 YVPKKTHVFYAAQN-UHFFFAOYSA-N 0.000 description 1
- WFKDDADPNCMDCZ-UHFFFAOYSA-N C1C(C=C2)=COC2=C1 Chemical compound C1C(C=C2)=COC2=C1 WFKDDADPNCMDCZ-UHFFFAOYSA-N 0.000 description 1
- YVHBSYTYLQYTOU-UHFFFAOYSA-N C1C2NC1CNC2 Chemical compound C1C2NC1CNC2 YVHBSYTYLQYTOU-UHFFFAOYSA-N 0.000 description 1
- UKHJNJFJCGBKSF-UHFFFAOYSA-N C1C2NCC1NC2 Chemical compound C1C2NCC1NC2 UKHJNJFJCGBKSF-UHFFFAOYSA-N 0.000 description 1
- DIQOUXNTSMWQSA-UHFFFAOYSA-N C1C2OCC1NC2 Chemical compound C1C2OCC1NC2 DIQOUXNTSMWQSA-UHFFFAOYSA-N 0.000 description 1
- VJKNAEZWNVUHAF-VQTJNVASSA-N CC(C)N(CC1)CCN1c([n]12)cccc1nc([C@@H](CCC1)N(C)[C@@H]1c(nccc1)c1Cl)c2Cl Chemical compound CC(C)N(CC1)CCN1c([n]12)cccc1nc([C@@H](CCC1)N(C)[C@@H]1c(nccc1)c1Cl)c2Cl VJKNAEZWNVUHAF-VQTJNVASSA-N 0.000 description 1
- CTKHJJPOGHSDRV-VQTJNVASSA-N CC(C)N(CC1)CCN1c([n]12)cccc1nc([C@@H](CCC1)N(C)[C@@H]1c(nccc1)c1Cl)c2F Chemical compound CC(C)N(CC1)CCN1c([n]12)cccc1nc([C@@H](CCC1)N(C)[C@@H]1c(nccc1)c1Cl)c2F CTKHJJPOGHSDRV-VQTJNVASSA-N 0.000 description 1
- ZFJYNKPPNRBFTH-FCHUYYIVSA-N CC(C)N(CC1)CCN1c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c3c(C)cccn3)c(CO)[n]12 Chemical compound CC(C)N(CC1)CCN1c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c3c(C)cccn3)c(CO)[n]12 ZFJYNKPPNRBFTH-FCHUYYIVSA-N 0.000 description 1
- SIZPIHICIYHVJQ-PKTZIBPZSA-N CC(C)N([C@H](CCC1)c2c[n]3c(N4CCN(C)CC4)cccc3n2)[C@@H]1c1c(C)cccn1 Chemical compound CC(C)N([C@H](CCC1)c2c[n]3c(N4CCN(C)CC4)cccc3n2)[C@@H]1c1c(C)cccn1 SIZPIHICIYHVJQ-PKTZIBPZSA-N 0.000 description 1
- KOMFSHQSMBSMKX-PKTZIBPZSA-N CC(C)c1c([C@H](CCC2)N(C)[C@H]2c2c[n]3c(N4CCN(C)CC4)cccc3n2)nccc1 Chemical compound CC(C)c1c([C@H](CCC2)N(C)[C@H]2c2c[n]3c(N4CCN(C)CC4)cccc3n2)nccc1 KOMFSHQSMBSMKX-PKTZIBPZSA-N 0.000 description 1
- ASIBQPPRHGMYRV-UHFFFAOYSA-N CC(CC=C1)NC1=N Chemical compound CC(CC=C1)NC1=N ASIBQPPRHGMYRV-UHFFFAOYSA-N 0.000 description 1
- HXVSCNSWQUNVQU-NRRUETGQSA-N CC(N([C@@H]1CCC2)[C@@H]2c2c(C)cccn2)[ClH]c2c1nc1[n]2c(N2CCN(C)CC2)ccc1 Chemical compound CC(N([C@@H]1CCC2)[C@@H]2c2c(C)cccn2)[ClH]c2c1nc1[n]2c(N2CCN(C)CC2)ccc1 HXVSCNSWQUNVQU-NRRUETGQSA-N 0.000 description 1
- RMTXSHIMDOGRNW-QFXXITGJSA-N CC/C=N/C/C=C/C Chemical compound CC/C=N/C/C=C/C RMTXSHIMDOGRNW-QFXXITGJSA-N 0.000 description 1
- PIPWSBOFSUJCCO-UHFFFAOYSA-N CC1(C)NCCNC1 Chemical compound CC1(C)NCCNC1 PIPWSBOFSUJCCO-UHFFFAOYSA-N 0.000 description 1
- DWARBTVEMLZQCW-SAOADBDPSA-N CC1N2C(N(CC3)CCN3C3CCOCC3)=CC=CC2=NC1[C@@H](CCC1)N(C)[C@@H]1c1c(C)cccn1 Chemical compound CC1N2C(N(CC3)CCN3C3CCOCC3)=CC=CC2=NC1[C@@H](CCC1)N(C)[C@@H]1c1c(C)cccn1 DWARBTVEMLZQCW-SAOADBDPSA-N 0.000 description 1
- JOMNTHCQHJPVAZ-UHFFFAOYSA-N CC1NCCNC1 Chemical compound CC1NCCNC1 JOMNTHCQHJPVAZ-UHFFFAOYSA-N 0.000 description 1
- MHASERYOVSJGAR-RBUKOAKNSA-N CCN(CC1)CCN1c([n]12)cccc1nc([C@@H](CCC1)N(C)[C@@H]1c(nccc1)c1Cl)c2Cl Chemical compound CCN(CC1)CCN1c([n]12)cccc1nc([C@@H](CCC1)N(C)[C@@H]1c(nccc1)c1Cl)c2Cl MHASERYOVSJGAR-RBUKOAKNSA-N 0.000 description 1
- RFPBBQHDUGKCKW-LOSJGSFVSA-N CCN(CC1)CCN1c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c3c(C(C)C)cccn3)c(COCC)[n]12 Chemical compound CCN(CC1)CCN1c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c3c(C(C)C)cccn3)c(COCC)[n]12 RFPBBQHDUGKCKW-LOSJGSFVSA-N 0.000 description 1
- OBARYTISHKVXKC-UHFFFAOYSA-N CCNCCNCCCCC(C)(C)C Chemical compound CCNCCNCCCCC(C)(C)C OBARYTISHKVXKC-UHFFFAOYSA-N 0.000 description 1
- BJTUQUWXNCMQGA-UHFFFAOYSA-N CCOC(c(nc1[n]2c(Br)ccc1)c2F)=O Chemical compound CCOC(c(nc1[n]2c(Br)ccc1)c2F)=O BJTUQUWXNCMQGA-UHFFFAOYSA-N 0.000 description 1
- VJMNOJHFYDPFKP-UHFFFAOYSA-N CCOC(c1c[n]2c(Br)cccc2n1)=O Chemical compound CCOC(c1c[n]2c(Br)cccc2n1)=O VJMNOJHFYDPFKP-UHFFFAOYSA-N 0.000 description 1
- KDXGNSFLTHLKHA-BJKOFHAPSA-N CCOCc1c([C@@H](CCC2)N(C)[C@@H]2c2c(C)cccn2)nc2[n]1c(N(CC1)CCN1C(C)C)ccc2 Chemical compound CCOCc1c([C@@H](CCC2)N(C)[C@@H]2c2c(C)cccn2)nc2[n]1c(N(CC1)CCN1C(C)C)ccc2 KDXGNSFLTHLKHA-BJKOFHAPSA-N 0.000 description 1
- KXPSPKWWKRKKSH-BJKOFHAPSA-N CCOCc1c([C@@H](CCC2)N(C)[C@@H]2c2c(C)cccn2)nc2[n]1c(N(CC1)CCN1C1CC1)ccc2 Chemical compound CCOCc1c([C@@H](CCC2)N(C)[C@@H]2c2c(C)cccn2)nc2[n]1c(N(CC1)CCN1C1CC1)ccc2 KXPSPKWWKRKKSH-BJKOFHAPSA-N 0.000 description 1
- QLXRANTXWNPMIO-ZYKFHVCXSA-N CN(C(CC1)C2)C1CN2c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c3ncccc3Cl)c(N)[n]12 Chemical compound CN(C(CC1)C2)C1CN2c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c3ncccc3Cl)c(N)[n]12 QLXRANTXWNPMIO-ZYKFHVCXSA-N 0.000 description 1
- KCZBSPPSZWKMOE-VQTJNVASSA-N CN(C)C(CC1)CCN1c([n]12)cccc1nc([C@@H](CCC1)N(C)[C@@H]1c(nccc1)c1Cl)c2Cl Chemical compound CN(C)C(CC1)CCN1c([n]12)cccc1nc([C@@H](CCC1)N(C)[C@@H]1c(nccc1)c1Cl)c2Cl KCZBSPPSZWKMOE-VQTJNVASSA-N 0.000 description 1
- NRQSICPUUTWMEP-VQTJNVASSA-N CN(C)C(CC1)CCN1c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c(nccc3)c3Cl)c(N)[n]12 Chemical compound CN(C)C(CC1)CCN1c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c(nccc3)c3Cl)c(N)[n]12 NRQSICPUUTWMEP-VQTJNVASSA-N 0.000 description 1
- QSPATAVPZRFHKY-ZWKOTPCHSA-N CN(CC1)CCN1c([n]12)cccc1nc([C@@H](CCC1)N(C)[C@@H]1c1c(C(F)(F)F)cccn1)c2F Chemical compound CN(CC1)CCN1c([n]12)cccc1nc([C@@H](CCC1)N(C)[C@@H]1c1c(C(F)(F)F)cccn1)c2F QSPATAVPZRFHKY-ZWKOTPCHSA-N 0.000 description 1
- QRHFTFJGHOVZHY-VQTJNVASSA-N CN(CC1)CCN1c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c3c(C(F)(F)F)cccn3)c(COC)[n]12 Chemical compound CN(CC1)CCN1c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c3c(C(F)(F)F)cccn3)c(COC)[n]12 QRHFTFJGHOVZHY-VQTJNVASSA-N 0.000 description 1
- HTKVSXNFPSPXKF-ZWKOTPCHSA-N CN(CC1)CCN1c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c3ncccc3Cl)c(N)[n]12 Chemical compound CN(CC1)CCN1c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c3ncccc3Cl)c(N)[n]12 HTKVSXNFPSPXKF-ZWKOTPCHSA-N 0.000 description 1
- JSYZRETYSXDPFW-ZYKFHVCXSA-N CN(CC1CC2)CC2N1c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c(nccc3)c3Cl)c(N)[n]12 Chemical compound CN(CC1CC2)CC2N1c1cccc2nc([C@@H](CCC3)N(C)[C@@H]3c(nccc3)c3Cl)c(N)[n]12 JSYZRETYSXDPFW-ZYKFHVCXSA-N 0.000 description 1
- GGACZVMYUPYTQX-GFULKKFKSA-N Cc1c(/C=C/C(/C=C/c(nc2[n]3cccc2)c3N2CCN(C)CC2)=O)nccc1 Chemical compound Cc1c(/C=C/C(/C=C/c(nc2[n]3cccc2)c3N2CCN(C)CC2)=O)nccc1 GGACZVMYUPYTQX-GFULKKFKSA-N 0.000 description 1
- JPLKJAFZEDVAAE-UHFFFAOYSA-N Cc1c(C(CC(C2)=O)N(C)C2c2c[n]3c(N4CCNCC4)cccc3n2)nccc1 Chemical compound Cc1c(C(CC(C2)=O)N(C)C2c2c[n]3c(N4CCNCC4)cccc3n2)nccc1 JPLKJAFZEDVAAE-UHFFFAOYSA-N 0.000 description 1
- DZYAFPAMOAKYQL-MOPGFXCFSA-N Cc1c([C@@H](CCC2)N(C)[C@@H]2c(nc2[n]3c(N4CCN(C)CC4)ccc2)c3Cl)nccc1 Chemical compound Cc1c([C@@H](CCC2)N(C)[C@@H]2c(nc2[n]3c(N4CCN(C)CC4)ccc2)c3Cl)nccc1 DZYAFPAMOAKYQL-MOPGFXCFSA-N 0.000 description 1
- XCHCGSNKJCUYBM-LEWJYISDSA-N Cc1c([C@@H](CCC2)N(C)[C@@H]2c2c[n]3c(N4CCN(C)CC4)cccc3n2)nccc1 Chemical compound Cc1c([C@@H](CCC2)N(C)[C@@H]2c2c[n]3c(N4CCN(C)CC4)cccc3n2)nccc1 XCHCGSNKJCUYBM-LEWJYISDSA-N 0.000 description 1
- PGLOSMWHIGEBJH-PKTZIBPZSA-N Cc1c([C@H](CCC2)N(C)[C@H]2c2c[n]3c(N(CC4)CCN4C4COC4)cccc3n2)nccc1 Chemical compound Cc1c([C@H](CCC2)N(C)[C@H]2c2c[n]3c(N(CC4)CCN4C4COC4)cccc3n2)nccc1 PGLOSMWHIGEBJH-PKTZIBPZSA-N 0.000 description 1
- URBDHSGAUQCNMX-PKTZIBPZSA-N Cc1c([C@H](CCC2)N(CCCO)[C@H]2c2c[n]3c(N4CCN(C)CC4)cccc3n2)nccc1 Chemical compound Cc1c([C@H](CCC2)N(CCCO)[C@H]2c2c[n]3c(N4CCN(C)CC4)cccc3n2)nccc1 URBDHSGAUQCNMX-PKTZIBPZSA-N 0.000 description 1
- YTVPPFLXRJAVSJ-DFIYOIEZSA-N Cc1c([C@H](CCC[C@@H]23)N2O[C@@H](C2CCN(C)CC2)c2c3nc3[n]2cccc3)nccc1 Chemical compound Cc1c([C@H](CCC[C@@H]23)N2O[C@@H](C2CCN(C)CC2)c2c3nc3[n]2cccc3)nccc1 YTVPPFLXRJAVSJ-DFIYOIEZSA-N 0.000 description 1
- YTVPPFLXRJAVSJ-WZOHSFFVSA-N Cc1c([C@H](CCC[C@@H]23)N2O[C@H](C2CCN(C)CC2)c2c3nc3[n]2cccc3)nccc1 Chemical compound Cc1c([C@H](CCC[C@@H]23)N2O[C@H](C2CCN(C)CC2)c2c3nc3[n]2cccc3)nccc1 YTVPPFLXRJAVSJ-WZOHSFFVSA-N 0.000 description 1
- RKGVLRIDAMKDLF-UHFFFAOYSA-N Cc1c[n]2c(N3CCN(C)CC3)c(C(CC(C3)=O)NC3c3c(C)cccn3)nc2cc1 Chemical compound Cc1c[n]2c(N3CCN(C)CC3)c(C(CC(C3)=O)NC3c3c(C)cccn3)nc2cc1 RKGVLRIDAMKDLF-UHFFFAOYSA-N 0.000 description 1
- MJOUJKDTBGXKIU-UHFFFAOYSA-N FC1(CCNCC1)F Chemical compound FC1(CCNCC1)F MJOUJKDTBGXKIU-UHFFFAOYSA-N 0.000 description 1
- BKLJUYPLUWUEOQ-UHFFFAOYSA-N Nc1nc(Br)ccc1 Chemical compound Nc1nc(Br)ccc1 BKLJUYPLUWUEOQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662352820P | 2016-06-21 | 2016-06-21 | |
| US201762456526P | 2017-02-08 | 2017-02-08 | |
| PCT/US2017/038609 WO2017223239A1 (en) | 2016-06-21 | 2017-06-21 | Cxcr4 inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2870920T3 true ES2870920T3 (es) | 2021-10-28 |
Family
ID=60783547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17816163T Active ES2870920T3 (es) | 2016-06-21 | 2017-06-21 | Inhibidores de CXCR4 y usos de los mismos |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US10759796B2 (enExample) |
| EP (2) | EP3471727B1 (enExample) |
| JP (2) | JP7054529B2 (enExample) |
| CN (2) | CN116554168B (enExample) |
| CA (1) | CA3027498A1 (enExample) |
| ES (1) | ES2870920T3 (enExample) |
| WO (1) | WO2017223239A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017070089A1 (en) | 2015-10-19 | 2017-04-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| SG10202004618TA (en) | 2015-11-19 | 2020-06-29 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| CN109069426B (zh) | 2015-12-14 | 2021-10-29 | X4 制药有限公司 | 治疗癌症的方法 |
| CA3008279A1 (en) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| MA44075A (fr) | 2015-12-17 | 2021-05-19 | Incyte Corp | Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1 |
| WO2017112894A1 (en) | 2015-12-22 | 2017-06-29 | X4 Pharmaceuticals, Inc. | Methods for treating immunodeficiency disease |
| AU2016379372A1 (en) | 2015-12-22 | 2018-08-02 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| CA3019394A1 (en) | 2016-04-08 | 2017-10-12 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| AR108396A1 (es) | 2016-05-06 | 2018-08-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| WO2017205464A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| HUE060256T2 (hu) | 2016-06-20 | 2023-02-28 | Incyte Corp | Heterociklusos vegyületek mint immunmodulátorok |
| ES2870920T3 (es) | 2016-06-21 | 2021-10-28 | X4 Pharmaceuticals Inc | Inhibidores de CXCR4 y usos de los mismos |
| CN109640988A (zh) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| EP3472129A4 (en) | 2016-06-21 | 2019-12-04 | X4 Pharmaceuticals, Inc. | CXCR4 INHIBITORS AND USES THEREOF |
| EP3484866B1 (en) | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2018044783A1 (en) | 2016-08-29 | 2018-03-08 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| JP7101678B2 (ja) | 2016-12-22 | 2022-07-15 | インサイト・コーポレイション | 免疫調節剤としての複素環式化合物 |
| ES2874756T3 (es) | 2016-12-22 | 2021-11-05 | Incyte Corp | Derivados de triazolo[1,5-A]piridina como inmunomoduladores |
| US20180179202A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2018119221A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| AU2018225556A1 (en) | 2017-02-21 | 2019-10-03 | Emory University | Chemokine CXCR4 receptor modulators and uses related thereto |
| US11649235B2 (en) | 2018-03-19 | 2023-05-16 | Emory University | Pan-tropic entry inhibitors |
| SMT202500157T1 (it) | 2018-03-30 | 2025-05-12 | Incyte Corp | Composti eterociclici come immunomodulatori |
| HUE061503T2 (hu) | 2018-05-11 | 2023-07-28 | Incyte Corp | Tetrahidro-imidazo[4,5-C]piridin-származékok mint PD-L1 immunmodulátorok |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| CA3144650A1 (en) * | 2019-06-26 | 2020-12-30 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| JP7665593B2 (ja) | 2019-08-09 | 2025-04-21 | インサイト・コーポレイション | Ｐｄ－１／ｐｄ－ｌ１阻害剤の塩 |
| EP4039331A4 (en) | 2019-09-30 | 2024-01-17 | Nippon Chemiphar Co., Ltd. | Azepan derivative |
| PE20221038A1 (es) | 2019-09-30 | 2022-06-17 | Incyte Corp | Compuestos de pirido[3,2-d] pirimidina como inmunomoduladores |
| CA3160131A1 (en) | 2019-11-11 | 2021-05-20 | Incyte Corporation | Salts and crystalline forms of a pd-1/pd-l1 inhibitor |
| CA3171250A1 (en) | 2020-03-10 | 2021-09-16 | E. Lynne KELLEY | Methods for treating neutropenia |
| WO2021263203A1 (en) * | 2020-06-26 | 2021-12-30 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| US11857551B1 (en) | 2020-07-10 | 2024-01-02 | Ting Therapeutics Llc | Methods for the prevention and treatment of hearing loss |
| WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
| TW202233615A (zh) | 2020-11-06 | 2022-09-01 | 美商英塞特公司 | Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式 |
| CR20230230A (es) | 2020-11-06 | 2023-07-27 | Incyte Corp | Proceso para hacer un inhibidor de pd-1/pdl1 y sales y formas cristalinas del mismo |
| EP4444304A4 (en) * | 2021-12-09 | 2025-12-17 | X4 Pharmaceuticals Inc | METHOD FOR THE TREATMENT OF PRIMARY IMMUNE DISCOMFORT |
| US20250326753A1 (en) * | 2022-03-25 | 2025-10-23 | X4 Pharmaceuticals, Inc. | Dual cxcr4-btk inhibitors |
| CN115403510B (zh) * | 2022-08-11 | 2023-04-25 | 南方医科大学 | 一种pd-l1/cxcl12双靶点抑制剂、制备方法和用途 |
| WO2024092069A1 (en) * | 2022-10-26 | 2024-05-02 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors for treatment of neurological diseases |
Family Cites Families (154)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| US4933447A (en) | 1987-09-24 | 1990-06-12 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
| US5021409A (en) | 1989-12-21 | 1991-06-04 | Johnson Matthey Plc | Antiviral cyclic polyamines |
| US6001826A (en) | 1989-12-21 | 1999-12-14 | Anormed, Inc. | Chemical compounds |
| GB9126677D0 (en) | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
| GB9200245D0 (en) | 1992-01-07 | 1992-02-26 | British Bio Technology | Compounds |
| US5235056A (en) | 1992-04-22 | 1993-08-10 | Ciba-Geigy Corporation | Substituted 1-hydroxy-2,6-diaryl-4-piperidone ketals and polymer compositions stabilized therewith |
| GB9400411D0 (en) | 1994-01-11 | 1994-03-09 | Johnson Matthey Plc | Improvements in chemical compounds |
| US6506770B1 (en) | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
| GB9511357D0 (en) | 1995-06-06 | 1995-08-02 | Johnson Matthey Plc | Improved antiviral compounds |
| AU6887996A (en) | 1995-09-01 | 1997-04-01 | Washington University School Of Medicine | Method of reducing neurotoxic injury with zinc chelators |
| PL329070A1 (en) | 1996-03-22 | 1999-03-15 | Du Pont Pharm Co | Novel dissymetrical synthesis of r-alpha-propylpiperonylamine and its analoques |
| AU740603B2 (en) | 1997-06-02 | 2001-11-08 | Janssen Pharmaceutica N.V. | (imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation |
| CA2296314A1 (en) | 1997-07-25 | 1999-02-04 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
| KR20010015639A (ko) | 1997-09-30 | 2001-02-26 | 스즈키 다다시 | 술포닐 유도체 |
| GB9726229D0 (en) | 1997-12-12 | 1998-02-11 | Zeneca Ltd | Resolution of chiral amines |
| EP1039899A2 (en) | 1997-12-19 | 2000-10-04 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative |
| US6607799B1 (en) | 1998-10-15 | 2003-08-19 | 3M Innovative Properties Company | Surgical dressing with delivery system and method of manufacture |
| DE19840028A1 (de) | 1998-09-02 | 2000-03-09 | Max Planck Gesellschaft | Nucleinsäuremoleküle codierend Enzyme, die Fructosyltransferaseaktivität besitzen, und deren Verwendung |
| US6635278B1 (en) | 1998-12-15 | 2003-10-21 | Gilead Sciences, Inc. | Pharmaceutical formulations |
| US6365583B1 (en) | 1999-02-02 | 2002-04-02 | Anormed, Inc. | Methods to enhance white blood cell count |
| AP1654A (en) | 1999-03-24 | 2006-09-01 | Anormed Inc | Chemokine receptor binding heterocyclic compounds. |
| JP2003513970A (ja) | 1999-11-08 | 2003-04-15 | ワイス | 中枢神経系障害の治療のための［（インドール−３−イル）−シクロアルキル］−３−置換アゼチジン |
| US6245799B1 (en) | 1999-11-08 | 2001-06-12 | American Home Products Corp | [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders |
| DE60037345T2 (de) | 1999-12-10 | 2008-11-13 | Pfizer Products Inc., Groton | Pyrrolo(2,3-d)pyrimidin-Verbindungen |
| US6602872B1 (en) | 1999-12-13 | 2003-08-05 | Merck & Co., Inc. | Substituted pyridazines having cytokine inhibitory activity |
| US6683192B2 (en) | 2000-03-30 | 2004-01-27 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| HK1052011A1 (zh) | 2000-09-15 | 2003-08-29 | Anormed Inc. | 趋化因子受体结合杂环化合物 |
| US6734191B2 (en) | 2000-09-15 | 2004-05-11 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds |
| DE60137435D1 (de) | 2000-09-15 | 2009-03-05 | Anormed Inc | Chemokin rezeptor bindenden heterozyklische verbindungen |
| NZ526622A (en) | 2000-12-11 | 2006-07-28 | Amgen Sf Llc | CXCR3 antagonists |
| US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| GB0107228D0 (en) | 2001-03-22 | 2001-05-16 | Astrazeneca Ab | Chemical compounds |
| DE60217322T2 (de) | 2001-04-27 | 2007-10-04 | Zenyaku Kogyo K.K. | Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält |
| US6794379B2 (en) | 2001-06-06 | 2004-09-21 | Tularik Inc. | CXCR3 antagonists |
| US7169750B2 (en) | 2001-07-31 | 2007-01-30 | Anormed, Inc. | Methods to mobilize progenitor/stem cells |
| DK1411918T3 (da) | 2001-07-31 | 2012-04-23 | Genzyme Global S A R L | Fremgangsmåder til at mobilisere progenitor/stamceller |
| US8178123B2 (en) | 2001-08-29 | 2012-05-15 | Femina Pharma Incorporated | Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration |
| JP4431389B2 (ja) | 2001-09-12 | 2010-03-10 | アノーメッド インコーポレイティド | 鏡像異性的に純粋なアミノ置換縮合二環式環の合成 |
| US7354932B2 (en) | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| PL369856A1 (en) | 2001-12-21 | 2005-05-02 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| US7491544B2 (en) | 2002-05-20 | 2009-02-17 | New York University | Chiral piperidine and quinucledine ligands |
| US7074809B2 (en) | 2002-08-09 | 2006-07-11 | Astrazeneca Ab | Compounds |
| PT1536827E (pt) | 2002-08-14 | 2009-03-20 | Silence Therapeutics Ag | Utilização de proteína cinase n beta |
| EP1571146A4 (en) | 2002-12-10 | 2010-09-01 | Ono Pharmaceutical Co | NITROGENIC HETEROCYCLIC COMPOUNDS AND THEIR MEDICAL USE |
| AU2004228668B2 (en) | 2003-04-03 | 2011-10-27 | Park Funding, Llc | PI-3 kinase inhibitor prodrugs |
| WO2004091518A2 (en) | 2003-04-11 | 2004-10-28 | Anormed Inc. | Cxcr4 chemokine receptor binding compounds |
| US7501518B2 (en) * | 2003-04-22 | 2009-03-10 | Genzyme Corporation | Methods of making 2,6-diaryl piperidine derivatives |
| JP4778420B2 (ja) | 2003-04-22 | 2011-09-21 | アノーメッド インコーポレイティド | 増強された有効性を有するケモカインレセプタ結合複素環式化合物 |
| ES2382377T3 (es) | 2003-05-30 | 2012-06-07 | Gemin X Pharmaceuticals Canada Inc. | Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer |
| EP1692153A4 (en) | 2003-07-03 | 2007-03-21 | Univ Pennsylvania | INHIBITION OF EXPRESSION OF SYK-KINASE |
| US7498346B2 (en) | 2003-12-11 | 2009-03-03 | Genzyme Corporation | Chemokine receptor binding compounds |
| EP1730113B1 (en) | 2004-03-15 | 2016-12-28 | Genzyme Corporation | Process for the synthesis of a cxcr4 antagonist |
| CA2561718A1 (en) * | 2004-04-13 | 2005-10-27 | Icagen, Inc. | Polycyclic pyridines as potassium ion channel modulators |
| DE102004021716A1 (de) * | 2004-04-30 | 2005-12-01 | Grünenthal GmbH | Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen |
| WO2005113556A1 (en) | 2004-05-13 | 2005-12-01 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
| MX2007001514A (es) | 2004-08-02 | 2007-03-27 | Smithkline Beecham Corp | Compuestos quimicos. |
| WO2006023400A2 (en) | 2004-08-16 | 2006-03-02 | Smithkline Beecham Corporation | Chemical compounds |
| MX2007002679A (es) | 2004-09-02 | 2007-05-16 | Smithkline Beecham Corp | Compuestos quimicos. |
| WO2006036816A2 (en) | 2004-09-24 | 2006-04-06 | Smithkline Beecham Corporation | Chemical compounds |
| TW200619206A (en) | 2004-09-29 | 2006-06-16 | Anormed Inc | Chemokine-binding heterocyclic compound salts, and methods of use thereof |
| AU2006206458B2 (en) | 2005-01-19 | 2012-10-25 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| WO2006096444A2 (en) | 2005-03-04 | 2006-09-14 | Smithkline Beecham Corporation | Chemical compounds |
| PL1888550T3 (pl) | 2005-05-12 | 2014-12-31 | Abbvie Bahamas Ltd | Promotory apoptozy |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| ATE476529T1 (de) | 2005-07-08 | 2010-08-15 | Siemens Healthcare Diagnostics | Verfahren zur vorhersage und überwachung einer unmittelbaren reaktion auf eine krebstherapie |
| EP1904501A2 (en) | 2005-07-11 | 2008-04-02 | Smithkline Beecham Corporation | Chemical compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| CA2617436A1 (en) | 2005-08-02 | 2007-02-08 | Ineos Europe Limited | Diene polymerisation catalysts comprising two or more transition metals |
| US20070043012A1 (en) | 2005-08-19 | 2007-02-22 | Bridger Gary J | Methods to enhance chemotherapy |
| JP2009507795A (ja) | 2005-08-31 | 2009-02-26 | スミスクライン ビーチャム コーポレーション | 化合物 |
| US7989622B2 (en) | 2005-10-07 | 2011-08-02 | Exelixis, Inc. | Phosphatidylinositol 3-kinase inhibitors and methods of their use |
| JP5191391B2 (ja) | 2005-11-01 | 2013-05-08 | ターゲジェン インコーポレーティッド | キナーゼのビ−アリールメタ−ピリミジン阻害剤 |
| WO2007058322A1 (ja) | 2005-11-18 | 2007-05-24 | Ono Pharmaceutical Co., Ltd. | 塩基性基を含有する化合物およびその用途 |
| JP2009517474A (ja) | 2005-11-30 | 2009-04-30 | シェーリング コーポレイション | Ｃｃｒ５拮抗剤およびｃｘｃｒ４拮抗剤の組み合わせを含む組成物 |
| SG10202003901UA (en) | 2005-12-13 | 2020-05-28 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| JP2009524689A (ja) | 2006-01-25 | 2009-07-02 | スミスクライン ビーチャム コーポレーション | 化合物 |
| PE20070946A1 (es) | 2006-01-25 | 2007-10-16 | Smithkline Beecham Corp | COMPUESTOS DERIVADOS DE IMIDAZO[1,2-a]PIRIDINA COMO MODULADORES DEL RECEPTOR DE QUIMIOQUINA (CXCR4) |
| GB0605786D0 (en) | 2006-03-22 | 2006-05-03 | Glaxo Group Ltd | Compounds |
| WO2007129161A2 (en) | 2006-04-26 | 2007-11-15 | F. Hoffmann-La Roche Ag | Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor |
| MX2008014296A (es) | 2006-06-12 | 2009-03-06 | Pfizer Prod Inc | Antagonista de ccr5 para mejorar la restitucion inmunitaria y tratar la infeccion oportunista en pacientes con vih. |
| TWI482772B (zh) | 2006-08-21 | 2015-05-01 | Astrazeneca Ab | 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物 |
| DK2526933T3 (en) | 2006-09-22 | 2015-05-18 | Pharmacyclics Inc | Inhibitors of Bruton's tyrosine kinase |
| CN101631786A (zh) | 2006-12-20 | 2010-01-20 | 先灵公司 | 新颖的jnk抑制剂 |
| KR101566840B1 (ko) | 2007-03-12 | 2015-11-06 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 페닐 아미노 피리미딘 화합물 및 이의 용도 |
| WO2008118802A1 (en) | 2007-03-23 | 2008-10-02 | Regents Of The University Of Minnesota | Therapeutic compounds |
| EP1974729A1 (en) | 2007-03-28 | 2008-10-01 | Santhera Pharmaceuticals (Schweiz) AG | Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists |
| ES2395583T3 (es) * | 2007-05-10 | 2013-02-13 | Ge Healthcare Limited | IMIDAZOL (1,2-A)PIRIDINAS y compuestos relacionados con actividad frente a los receptores cannabinoides CB2 |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| CA2695989A1 (en) | 2007-08-10 | 2009-02-19 | Glaxosmithkline Llc | Certain nitrogen containing bicyclic chemical entities for treating viral infections |
| WO2009026251A1 (en) | 2007-08-17 | 2009-02-26 | The General Hospital Corporation | Detecting ions and measuring ion concentrations |
| US9101628B2 (en) | 2007-09-18 | 2015-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and composition of treating a flaviviridae family viral infection |
| US20110052562A1 (en) | 2007-12-19 | 2011-03-03 | The Scripps Research Institute | Benzimidazoles and analogs as rho kinase inhibitors |
| HUE029767T2 (en) | 2008-03-11 | 2017-04-28 | Incyte Holdings Corp | JAK inhibitor azetidine and cyclobutane derivatives |
| NZ588033A (en) | 2008-03-20 | 2012-11-30 | Carolus Therapeutics Inc | Methods of treating a mif-mediated disorder |
| BRPI0909375A2 (pt) | 2008-03-28 | 2015-08-04 | Altiris Therapeutics | Moduladores de receptores de quimiocinas |
| WO2009151910A2 (en) | 2008-05-25 | 2009-12-17 | Wyeth | Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| JP2010016628A (ja) | 2008-07-03 | 2010-01-21 | Canon Inc | 画像処理装置及び画像処理方法 |
| RS53347B (sr) | 2008-12-09 | 2014-10-31 | Gilead Sciences, Inc. | Modulatori toll-sličnih receptora |
| WO2011036270A1 (en) | 2009-09-28 | 2011-03-31 | Kerry Group Services International Limited | Pharmaceutical composition |
| WO2011050245A1 (en) | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
| CA2706292A1 (en) | 2010-05-28 | 2011-11-28 | Pharmascience Inc. | A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide |
| US20110293686A1 (en) | 2010-05-28 | 2011-12-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Anti-viral compositions and methods for administration |
| WO2012047339A2 (en) | 2010-06-28 | 2012-04-12 | The General Hospital Corporation | Anti-cxcr4 as a sensitizer to cancer therapeutics |
| US9079880B2 (en) | 2010-07-07 | 2015-07-14 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
| GB201017345D0 (en) * | 2010-10-14 | 2010-11-24 | Proximagen Ltd | Receptor antagonists |
| US9267934B2 (en) | 2010-10-26 | 2016-02-23 | University Of South Alabama | Methods and compositions for ameliorating pancreatic cancer |
| CA2815179A1 (en) | 2010-11-10 | 2012-05-18 | Actelion Pharmaceuticals Ltd | Lactam derivatives useful as orexin receptor antagonists |
| AU2011336397B2 (en) | 2010-12-03 | 2016-12-15 | Emory University | Chemokine CXCR4 receptor modulators and uses related thereto |
| US8435993B2 (en) | 2010-12-07 | 2013-05-07 | Philadelphia Health And Education Corporation | Methods of inhibiting metastasis from cancer |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CN107899012A (zh) | 2011-01-11 | 2018-04-13 | 戴麦里克斯生物科学有限公司 | 联合疗法 |
| KR20140045411A (ko) | 2011-05-16 | 2014-04-16 | 젠자임 코포레이션 | Ｃｘｃｒ４ 길항제의 용도 |
| AR087364A1 (es) | 2011-07-29 | 2014-03-19 | Pf Medicament | Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres |
| CA2849820C (en) | 2011-09-26 | 2019-08-27 | Merck Patent Gmbh | Benzyl piperidine compounds as lysophosphatidic acid (lpa) receptor antagonist |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| CA2860995A1 (en) | 2012-01-12 | 2013-07-18 | Gilead Sciences, Inc. | Pharmaceutical compositions and methods for their preparation |
| WO2014082083A1 (en) | 2012-11-26 | 2014-05-30 | Caris Science, Inc. | Biomarker compositions and methods |
| MX2015012549A (es) * | 2013-03-15 | 2016-06-21 | Abbvie Deutschland | Formulaciones de conjugado anticuerpo anti-egfr-farmaco. |
| US10064826B2 (en) | 2013-03-15 | 2018-09-04 | Navinta, Llc | Direct compression and dry granulation processes for preparing carglumic acid tablets having less impurities than those produced by wet granulation process |
| EP3473299A1 (en) | 2013-06-05 | 2019-04-24 | Salk Institute for Biological Studies | Vitamin d receptor agonists to treat diseases involving cxcl12 activity |
| JO3425B1 (ar) | 2013-07-15 | 2019-10-20 | Novartis Ag | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b |
| CA2920377A1 (en) | 2013-08-05 | 2015-02-12 | Cambridge Enterprise Limited | Inhibition of cxcr4 signaling in cancer immunotherapy |
| PT3038601T (pt) | 2013-08-27 | 2020-06-30 | Gilead Pharmasset Llc | Formulação combinada de dois compostos antivirais |
| AU2014318614B2 (en) | 2013-09-12 | 2021-01-07 | Dana-Farber Cancer Institute Inc. | Methods for evaluating and treating Waldenstrom's macroglobulinemia |
| IL292510A (en) | 2013-11-05 | 2022-06-01 | Cognate Bioservices Inc | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
| WO2015143092A1 (en) | 2014-03-18 | 2015-09-24 | The Research Foundation For The State University Of New York | Therapeutic agent for treating tumors |
| MX382033B (es) | 2014-03-19 | 2025-03-13 | Infinity Pharmaceuticals Inc | Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma. |
| WO2015200341A1 (en) * | 2014-06-23 | 2015-12-30 | Dr. Reddy's Laboratories Ltd. | Substituted imidazo[1,2-a]pyridine compounds useful for the treatment of pain |
| RU2696312C2 (ru) | 2014-07-16 | 2019-08-01 | Трансген Са | Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек |
| CA2970114A1 (en) | 2014-12-12 | 2016-06-16 | Commonwealth Scientific And Industrial Research Organisation | Dislodgement and release of hsc using alpha 9 integrin antagonist and cxcr4 antagonist |
| US20180133327A1 (en) | 2015-03-16 | 2018-05-17 | Amal Therapeutics Sa | Cell Penetrating Peptides and Complexes Comprising the Same |
| JP2018516969A (ja) | 2015-06-12 | 2018-06-28 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｐｄ−１およびｃｘｃｒ４シグナル伝達経路の組合せ遮断による癌の処置 |
| WO2017048702A1 (en) | 2015-09-14 | 2017-03-23 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
| US10379661B2 (en) | 2015-09-25 | 2019-08-13 | Samsung Electronics Co., Ltd. | Coordinate measuring apparatus and coordinate measuring system having the same |
| CA3008279A1 (en) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| CN109069426B (zh) | 2015-12-14 | 2021-10-29 | X4 制药有限公司 | 治疗癌症的方法 |
| WO2017112894A1 (en) | 2015-12-22 | 2017-06-29 | X4 Pharmaceuticals, Inc. | Methods for treating immunodeficiency disease |
| CN108883132A (zh) | 2016-01-22 | 2018-11-23 | X4 制药有限公司 | 用于治疗癌症的方法 |
| CA3019394A1 (en) | 2016-04-08 | 2017-10-12 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| JP7128399B2 (ja) | 2016-04-14 | 2022-08-31 | クリエイティブ マイクロテック インコーポレーテッド | 癌治療のための治療決定におけるｐｄ－ｌ１発現の使用方法 |
| CN109640988A (zh) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| ES2870920T3 (es) | 2016-06-21 | 2021-10-28 | X4 Pharmaceuticals Inc | Inhibidores de CXCR4 y usos de los mismos |
| EP3472129A4 (en) | 2016-06-21 | 2019-12-04 | X4 Pharmaceuticals, Inc. | CXCR4 INHIBITORS AND USES THEREOF |
| JP2020525427A (ja) | 2017-06-21 | 2020-08-27 | エックス４ ファーマシューティカルズ， インコーポレイテッド | 癌を処置するための方法 |
| JP2021502071A (ja) | 2017-11-07 | 2021-01-28 | エックス４ ファーマシューティカルズ， インコーポレイテッド | がんバイオマーカーおよびその使用方法 |
| WO2019126106A1 (en) | 2017-12-19 | 2019-06-27 | X4 Pharmaceuticals, Inc. | Acyclic cxcr4 inhibitors and uses thereof |
| WO2019200223A1 (en) | 2018-04-13 | 2019-10-17 | X4 Pharmaceuticals, Inc. | Cancer serum biomarkers and methods of use thereof |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
-
2017
- 2017-06-21 ES ES17816163T patent/ES2870920T3/es active Active
- 2017-06-21 CA CA3027498A patent/CA3027498A1/en active Pending
- 2017-06-21 EP EP17816163.4A patent/EP3471727B1/en active Active
- 2017-06-21 CN CN202310296466.XA patent/CN116554168B/zh active Active
- 2017-06-21 JP JP2018566969A patent/JP7054529B2/ja active Active
- 2017-06-21 US US16/311,020 patent/US10759796B2/en active Active
- 2017-06-21 CN CN201780048803.6A patent/CN109562106B/zh active Active
- 2017-06-21 WO PCT/US2017/038609 patent/WO2017223239A1/en not_active Ceased
- 2017-06-21 EP EP20212271.9A patent/EP3808748A1/en active Pending
-
2020
- 2020-07-27 US US16/939,723 patent/US11306088B2/en active Active
-
2022
- 2022-03-14 US US17/654,722 patent/US11780837B2/en active Active
- 2022-03-28 JP JP2022051875A patent/JP7402549B2/ja active Active
-
2023
- 2023-09-12 US US18/465,823 patent/US20240150350A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022076020A (ja) | 2022-05-18 |
| US20210047320A1 (en) | 2021-02-18 |
| US11780837B2 (en) | 2023-10-10 |
| EP3808748A1 (en) | 2021-04-21 |
| JP7402549B2 (ja) | 2023-12-21 |
| CN109562106B (zh) | 2023-03-21 |
| US11306088B2 (en) | 2022-04-19 |
| CN109562106A (zh) | 2019-04-02 |
| JP2019518767A (ja) | 2019-07-04 |
| CA3027498A1 (en) | 2017-12-28 |
| EP3471727A4 (en) | 2019-10-09 |
| US10759796B2 (en) | 2020-09-01 |
| US20200123150A1 (en) | 2020-04-23 |
| US20220372032A1 (en) | 2022-11-24 |
| WO2017223239A1 (en) | 2017-12-28 |
| CN116554168A (zh) | 2023-08-08 |
| EP3471727B1 (en) | 2020-12-09 |
| US20240150350A1 (en) | 2024-05-09 |
| JP7054529B2 (ja) | 2022-04-14 |
| CN116554168B (zh) | 2025-09-23 |
| EP3471727A1 (en) | 2019-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2870920T3 (es) | Inhibidores de CXCR4 y usos de los mismos | |
| JP6994767B2 (ja) | Ｃｘｃｒ４阻害剤およびその使用 | |
| JP7084624B2 (ja) | Ｃｘｃｒ４阻害剤およびその使用 | |
| TW202108571A (zh) | Tead抑制劑及其用途 | |
| EP4323066A1 (en) | Mek inhibitors and uses thereof | |
| EP3846793B1 (en) | Eif4e inhibitors and uses thereof | |
| ES2987356T3 (es) | Compuestos antiproliferación y usos de los mismos | |
| WO2022187849A1 (en) | Salinomycin derivatives and uses thereof | |
| WO2020264292A1 (en) | Cxcr4 inhibitors and uses thereof | |
| HK40050670A (en) | Substituted piperidines as cxcr4-inhibitors | |
| HK40006048B (en) | Cxcr4 inhibitors and uses thereof | |
| HK40006048A (en) | Cxcr4 inhibitors and uses thereof | |
| EA047483B1 (ru) | Ингибиторы tead и их применения |